Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9604572 | 0.85 | CYP1A2 (0.69) | ADORA1ADORA2ACYP1A2CYP2D6MAPK1 | |
| SCHEMBL6438354 | 0.83 | ADORA1 (0.54) | ADORA1ADORA2ACYP1A2CYP2D6MAPK1 | |
| SCHEMBL6438168 | 0.79 | ADORA1 (0.50) | ADORA1ADORA2ACYP1A2CYP2D6MAPK1 | |
| SCHEMBL6364457 | 0.78 | ADORA2A (0.61) | ADORA1ADORA2ACYP1A2CYP2D6MAPK1 | |
| SCHEMBL14566369 | 0.76 | CDK1 (0.51) | ADORA1ADORA2ACYP1A2CYP2D6MAPK1 | |
| SCHEMBL13415584 | 0.73 | YTHDC1 (0.45) | ADORA1ADORA2ACYP1A2CYP2D6MAPK1 | |
| SCHEMBL106573 | 0.73 | ADORA2A (1.00) | ADORA1ADORA2AYTHDC1CDK1 | |
| SCHEMBL7147821 | 0.72 | ADORA2A (0.96) | ADORA1ADORA2AYTHDC1CDK1 | |
| SCHEMBL7140260 | 0.72 | ADORA2A (0.96) | ADORA1ADORA2AYTHDC1CDK1 | |
| SCHEMBL441875 | 0.71 | ADORA1 (0.62) | ADORA1ADORA2ACYP1A2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2007027248-A2 | 3', 5' - CYCLIC NUCLEOSIDE ANALOGUES FOR TREATMENT OF HCV | VALEANT RESEARCH & DEVELOPMENT (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | ADORA1 163/4885ADORA2A 102/4885CYP1A2 4059/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | ADORA1 163/4885ADORA2A 102/4885CYP1A2 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.